Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) has shown a slight decline at the opening, with a reported drop of 0.47% to 1.490 yuan, reflecting market volatility and investor sentiment [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) has a performance benchmark based on the Zhongzheng 1000 Index return [1] - Since its establishment on August 31, 2023, the fund has achieved a return of 49.67% [1] - Over the past month, the fund has recorded a return of 1.29% [1] Group 2: Major Holdings - Key stocks in the fund include: - Xiangdian Co., Ltd. with a decline of 0.40% - Haoyuan Pharmaceutical down by 0.50% - New Qianglian up by 0.14% - Chujian New Materials down by 2.91% - Nanwei Software down by 0.42% - Zhenlei Technology up by 0.21% - Zhenxin Technology down by 0.42% - Yingliu Co., Ltd. down by 0.47% - Hongsoft Technology down by 0.57% - Bojun Technology up by 0.38% [1]

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) shows a slight decline of 0.53% as of the midday close, indicating market volatility and mixed performance among its constituent stocks [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) closed at 1.505 yuan with a trading volume of 3.3888 million yuan [1] - Since its establishment on August 31, 2023, the fund has achieved a return of 51.06%, with a monthly return of 3.28% [1] Group 2: Stock Performance - Among the top holdings, Xiangdian Co. fell by 1.99%, while Haoyuan Pharmaceutical rose by 2.10% [1] - Other notable stock movements include: Xinqianglian down 0.27%, Chujian New Materials up 7.18%, Nanwei Software down 1.95%, Zhenlei Technology down 2.95%, Zhenxin Technology down 1.10%, Yingliu Co. up 7.01%, Hongsoft Technology down 1.67%, and Bojun Technology down 0.72% [1]

Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical's stock has seen a significant increase, with a rise of 5.06% to 76.38 CNY per share, and a total market capitalization of 16.2 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the production and technical improvement of active pharmaceutical ingredients and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42%, active pharmaceutical ingredients and intermediates 30.46%, technical services 5.55%, and other sources 0.57% [1] Group 2 - According to data, Guotai Fund holds Haoyuan Pharmaceutical as a significant investment, with the Guotai Innovation Medical Mixed Fund A (018159) holding 14,000 shares, accounting for 3.93% of the fund's net value, ranking as the seventh largest holding [2] - The Guotai Innovation Medical Mixed Fund A was established on April 18, 2023, with a latest scale of 12.614 million CNY, and has achieved a year-to-date return of 50.31%, ranking 623 out of 8161 in its category [2] - The fund manager, Qiu Xiaoxu, has a tenure of 3 years and 62 days, with the fund's total asset size at 871 million CNY, achieving a best return of 19.63% and a worst return of 0.83% during the tenure [3]

Core Viewpoint - Haoyuan Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a cash dividend of 0.08 yuan per share (tax included) [2] Summary by Category Dividend Announcement - The cash dividend of 0.08 yuan per share is set to be distributed to shareholders [2] - The record date for the dividend is October 21, 2025, with the ex-dividend date and payment date both on October 22, 2025 [2]

Core Points - The company announced an adjustment in the total cash dividend amount for the first half of 2025, maintaining a cash dividend of 0.80 yuan per 10 shares (including tax) [2] - The total cash dividend amount was adjusted from 16,967,901.20 yuan (including tax) to 16,967,993.52 yuan (including tax) [2] - The adjustment is due to the increase in the number of shares participating in profit distribution as a result of the company's publicly issued "Haoyuan Convertible Bonds" being in the conversion period [2]

Market Overview - The medical services sector experienced a decline of 2.91% on October 13, with Haoyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the medical services sector included: - Meinian Health: closed at 5.29, up 3.52% with a trading volume of 2.2848 million shares [1] - ST Biological: closed at 9.15, up 2.69% with a trading volume of 23,400 shares [1] - International Medical: closed at 4.98, up 2.26% with a trading volume of 356,400 shares [1] - Major decliners included: - Haoyuan Pharmaceutical: closed at 75.50, down 6.79% with a trading volume of 75,700 shares [2] - Boteng Co.: closed at 23.34, down 6.27% with a trading volume of 224,900 shares [2] - Kailaiying: closed at 105.42, down 5.04% with a trading volume of 57,800 shares [2] Capital Flow - The medical services sector saw a net outflow of 870 million yuan from institutional investors, while retail investors contributed a net inflow of 601 million yuan [2][3] - Key stocks with significant capital flow included: - Sanbo Brain Science: net inflow of 21.51 million yuan from institutional investors [3] - International Medical: net inflow of 20.51 million yuan from institutional investors [3] - Jiuzhou Pharmaceutical: net inflow of 10.59 million yuan from institutional investors [3]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-117 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于实施 2025 年半年度权益分派调整可转债 转股价格暨转股复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2025 年半年度权益分派，上海皓元医药股份有限公司（以下简称"公 司"）的相关证券停复牌情况如下：权益分派实施公告披露日前一交易日（2025 年 10 月 13 日）至权益分派股权登记日（2025 年 10 月 21 日）期间，本公司可转 债将停止转股，2025 年 10 月 22 日起恢复转股。 | 证券代码 | 证券简称 | 停复牌类 | 停牌起 | 停牌期 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | 型 | 始日 | 间 | | | | 118051 | 皓 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-115 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整 2025 年半年度利润分配现金分红 总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 现金分红总额调整情况：上海皓元医药股份有限公司（以下简称"公 司"）2025 年半年度拟向全体股东每 10 股派发现金红利 0.80 元（含税）维持不 变，派发现金红利总额由 16,967,901.20 元（含税）调整为 16,967,993.52 元（含 税）。 本次调整原因：因公司公开发行的"皓元转债"目前处于转股期内，导 致公司实际参与利润分配的股份数量增加，公司拟维持每股分配金额不变，相 应调整 2025 年半年度现金分配总额。 一、调整前利润分配方案 根据公司 2024 年年度股东大会的授权，公司分别于 2025 年 8 月 26 日召开 第四届董事会审计委员会第五次会议、2025 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-116 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/21 | 2025/10/22 | 2025/10/22 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 4 月 18 日的2024年年度股东大会授权公司董 事会制定，并经公司 2025 年 8 月 27 日召开的第四届董事会第十一次会议审议通 过后实施。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1 是 ...

Group 1 - The core point of the article highlights the recent decline in the stock price of Haoyuan Pharmaceutical, which fell by 5.05% to 76.91 CNY per share, with a trading volume of 178 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 16.313 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales accounting for 63.42%, APIs and intermediates contributing 30.46%, and technical services making up 5.55% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a significant position in the Hongta Hongtu Fund, specifically in the Hongta Hongtu Medical Selected Stock A Fund (020331), which holds 13,000 shares, representing 4.93% of the fund's net value, ranking as the fourth-largest holding [2] - The Hongta Hongtu Medical Selected Stock A Fund (020331) was established on April 2, 2024, with a latest scale of 11.6663 million CNY, achieving a year-to-date return of 32.35%, ranking 1626 out of 4220 in its category, and a one-year return of 20.3%, ranking 2324 out of 3855 [2]